查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930165

全球腦膜炎雙球菌疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Meningococcal Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 161 Pages | 商品交期: 請詢問到貨日

價格

腦膜炎雙球菌疫苗市場成長驅動因子

受侵襲性腦膜炎雙球菌疾病發生率上升、疫苗接種計畫擴大以及疫苗技術持續創新等因素的推動，全球腦膜炎雙球菌疫苗市場持續穩定成長。在2025年報告期內，市場規模達到106.1億美元，反映出人們對預防由腦膜炎奈瑟菌引起的危及生命的感染的疫苗接種需求強勁。預計到2026年，市場規模將達到41.2億美元，並在2034年進一步擴大至92.4億美元，這主要得益於公眾意識的提高、政府主導的疫苗接種策略以及多種血清群疫苗接種覆蓋範圍的擴大。

腦膜炎雙球菌感染，包括腦膜炎和敗血症等嚴重疾病，若不及時治療，病情可能迅速惡化並危及生命。在已知的12個腦膜炎雙球菌血清群中，A、B、C、W、X和Y這六個血清群是全球疫情的主要病原體。由於腦膜炎雙球菌感染死亡率高，且可能引發腦損傷、聽力喪失和截肢等長期併發症，因此接種疫苗仍然是最有效的預防措施，從而支撐了市場需求的持續增長。

市場概覽及主要洞察

預計到2025年，北美將以13.36%的市場佔有率引領腦膜炎球菌疫苗市場，這得益於其先進的醫療保健體系、強大的監測基礎設施和完善的國家疫苗接種計劃。 受疾病發病率上升和積極的疫苗接種政策推動，預計到2025年，該地區市場規模將達到22.1億美元。美國在其中扮演著核心角色，這得益於報告病例的增加以及針對青少年、青年和高風險族群的疫苗產品持續獲得批准。

亞太地區是成長最快的區域市場，這得益於人們對疾病的認識不斷提高、世界衛生組織支持的疫苗接種計劃以及區域製造商提供的高性價比疫苗。歐洲憑藉成功的國家疫苗接種計劃和高疫苗接種率（尤其是在兒童群體中）保持著強勁的地位。

市場動態

市場驅動因素

全球細菌性腦膜炎發生率的上升是主要的成長因素。根據世界衛生組織（世衛組織）統計，六分之一的細菌性腦膜炎病例會導致死亡，五分之一的倖存者會留下永久性殘疾。 光是美國在2023年就報告了438例腦膜炎球菌疾病病例，這是過去十年來的最高數字。這些數據凸顯了廣泛接種疫苗的迫切性，並支撐了全球市場需求。

市場限制因子

腦膜炎雙球菌疫苗的高成本限制了其廣泛應用，尤其是在中低收入國家。結合疫苗和多價疫苗需要複雜的生產流程和嚴格的冷鏈物流，從而推高了整體成本。私部門疫苗價格超過每劑170-230美元，可能會限制無保險族群獲得疫苗的機會。

市場機會

政府主導的消除腦膜炎的努力帶來了強勁的成長機會。諸如 "2030年消除腦膜炎" 倡議等國際計畫正在推動高負擔地區提高免疫接種覆蓋率。世界衛生組織支持的經濟實惠的多價疫苗的推出有助於提高疫苗可及性並實現疾病的長期減少。

市場挑戰

對冷鏈的依賴以及儲存基礎設施不足仍然是重大挑戰。由於冷藏設備故障和停電造成的疫苗浪費持續給公共衛生系統帶來經濟負擔，並限制了資源匱乏地區疫苗的有效分發。

市場趨勢

影響市場的關鍵趨勢是五價（MenABCWY）疫苗的研發，該疫苗可預防五種最常見的致病血清群。這些疫苗簡化了接種程序，降低了物流複雜性，並提高了覆蓋率。近期五價疫苗獲得監管部門批准，正在加速其在青少年和成人疫苗接種計劃中的應用。

市場區隔分析

依技術分類

重組/結合/次單位疫苗細分市場佔最大的市場佔有率，這得益於其優異的免疫原性和持久的保護作用。 全液體單劑量結合疫苗等創新進一步鞏固了這個市場。滅活疫苗在疫情爆發期間的大規模疫苗接種活動中繼續發揮重要作用。

依類型

由於被納入青少年常規免疫接種計劃，MenACWY疫苗佔了市場主導地位。雖然MenB疫苗的需求保持穩定，但由於MenABCWY疫苗覆蓋範圍更廣且近期獲得批准，預計其成長速度將更快。

依年齡組

兒科市場佔主導地位，這主要得益於國家兒童免疫接種計劃和嬰幼兒疫苗使用範圍的擴大。高風險族群疾病發生率的上升也推動了成人疫苗的需求。

依分銷管道

政府供應商佔最大佔有率，他們利用批量採購和公共疫苗接種計劃來擴大市場佔有率。 醫院和零售藥局正在城市和半城市地區擴大疫苗的供應範圍。

"全球腦膜炎雙球菌疫苗市場（2025）" 報告對2025年、2026年和2034年的市場規模和價值進行了全面分析，涵蓋疾病流行病學、市場動態、技術趨勢、市場細分、區域展望、競爭格局和關鍵行業發展。該報告重點關注疫苗接種覆蓋率、監管環境、研發進展以及塑造腦膜炎雙球菌疾病預防未來的全球努力。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家的監管環境
  • 主要國家的疫苗接種覆蓋率
  • 主要國家的政府腦膜炎疫苗接種計劃
  • 腦膜炎雙球菌疫苗的技術進步
  • 主要產業趨勢：併購、商業合作等。

第五章：全球腦膜炎雙球菌疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依技術分類
    • 重組/結合/次單位疫苗
    • 滅活​​疫苗
    • 其他
  • 市場分析、洞察與預測：依類型分類
    • MenACWY疫苗
    • MenB疫苗
    • MenABCWY疫苗
    • 其他
  • 市場分析、洞察與預測：依年齡組別分類
    • 兒科
    • 成人
  • 市場分析、洞察與預測：依銷售管道分類
    • 醫院與零售通路藥房
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美腦膜炎雙球菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲腦膜炎雙球菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 美國王國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區腦膜炎雙球菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲腦膜炎雙球菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區美國

第十章：中東與非洲腦膜炎雙球菌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
    • GSK plc
    • Sanofi
    • Merck &Co., Inc.
    • Serum Institute of India Pvt. Ltd.
    • Novartis AG
    • Walvax Biotechnology Co., Ltd.
    • Hualan Biological Vaccine Inc.
    • Bio Farma
    • BioNet-Asia.
Product Code: FBI113758

Growth Factors of meningococcal vaccines Market

The global meningococcal vaccines market is experiencing consistent expansion, supported by the rising incidence of invasive meningococcal diseases, expanding immunization programs, and continuous innovation in vaccine technology. As per the 2025 report year, the market size stood at USD 10.61 billion in 2025, reflecting the strong demand for preventive vaccination against life-threatening infections caused by Neisseria meningitidis. The market is projected to reach USD 4.12 billion in 2026 and further expand to USD 9.24 billion by 2034, driven by increased awareness, government-backed immunization strategies, and broader vaccine coverage against multiple serogroups.

Meningococcal disease includes severe conditions such as meningitis and septicemia, which progress rapidly and can be fatal if untreated. Among the 12 known serogroups of N. meningitidis, six-A, B, C, W, X, and Y-are responsible for the majority of global epidemics. Due to high mortality and long-term complications such as brain damage, hearing loss, and limb amputation, vaccination remains the most effective preventive strategy, fueling sustained market demand.

Market Overview and Key Insights

In 2025, North America dominated the meningococcal vaccines market with a 13.36% share, supported by advanced healthcare systems, strong surveillance infrastructure, and established national immunization schedules. The region recorded a market size of USD 2.21 billion in 2025, driven by rising disease incidence and proactive vaccination policies. The U.S. plays a central role due to increased reported cases and continuous product approvals aimed at adolescents, young adults, and high-risk populations.

Asia Pacific represents the fastest-growing regional market, supported by rising disease awareness, WHO-backed vaccination programs, and the availability of cost-effective vaccines from regional manufacturers. Europe maintains a strong position due to successful national immunization programs and high vaccine coverage rates, particularly among pediatric populations.

Market Dynamics

Market Drivers

The increasing global incidence of bacterial meningitis is a primary growth driver. According to the World Health Organization, 1 in 6 individuals with bacterial meningitis die, and 1 in 5 survivors experience permanent disabilities. In the U.S. alone, 438 meningococcal disease cases were reported in 2023, the highest number in a decade. Such data underscores the urgent need for widespread vaccination, boosting global market demand.

Market Restraints

The high cost of meningococcal vaccines limits adoption, particularly in low- and middle-income countries. Conjugate and multivalent vaccines require complex manufacturing processes and strict cold-chain logistics, increasing overall costs. Private-sector vaccine prices exceeding USD 170-230 per dose may restrict access for uninsured populations.

Market Opportunities

Government initiatives aimed at eliminating meningitis present strong growth opportunities. Global programs such as "Defeating Meningitis by 2030" are expanding immunization coverage in high-burden regions. WHO-supported rollout of affordable multivalent vaccines is increasing access and supporting long-term disease reduction.

Market Challenges

Cold-chain dependency and inadequate storage infrastructure remain major challenges. Vaccine wastage due to refrigeration failures and power disruptions continues to impose financial burdens on public health systems, limiting efficient vaccine distribution in resource-constrained regions.

Market Trends

A key trend shaping the market is the development of pentavalent (MenABCWY) vaccines, offering protection against the five most prevalent disease-causing serogroups. These vaccines simplify immunization schedules, reduce logistical complexity, and improve coverage efficiency. Recent regulatory approvals for pentavalent vaccines are accelerating adoption across adolescent and adult vaccination programs.

Segmentation Analysis

By Technology

The recombinant/conjugate/subunit vaccines segment held the largest market share, supported by superior immunogenicity and long-lasting protection. Innovations such as fully liquid, single-vial conjugate vaccines are further strengthening this segment. Inactivated vaccines maintain relevance in outbreak-driven mass immunization campaigns.

By Type

The MenACWY vaccines segment dominated due to inclusion in routine adolescent immunization schedules. MenB vaccines maintain steady demand, while MenABCWY vaccines are expected to grow at a faster pace due to broader serogroup coverage and recent approvals.

By Age Group

The pediatric segment leads the market, driven by national childhood vaccination programs and expanded indications for infants. Adult vaccination demand is also increasing due to rising disease incidence among high-risk populations.

By Distribution Channel

Government suppliers account for the largest share, leveraging bulk procurement and public immunization initiatives. Hospital and retail pharmacies are expanding access in urban and semi-urban areas.

Competitive Landscape

The meningococcal vaccines market is consolidated, with major players including GSK plc, Sanofi, and Pfizer Inc. holding a substantial share due to diversified vaccine portfolios and continuous R&D investments. Other significant contributors include Serum Institute of India, Walvax Biotechnology, Bio Farma, and Hualan Biological Vaccine, supporting global supply through affordable and region-specific vaccine solutions.

Report Coverage

The 2025 meningococcal vaccines market report delivers a comprehensive analysis of market size and value for 2025, 2026, and 2034, covering disease epidemiology, market dynamics, technology trends, segmentation, regional outlook, competitive landscape, and key industry developments. The report emphasizes vaccination coverage, regulatory progress, pipeline advancements, and global initiatives shaping the future of meningococcal disease prevention.

Conclusion

The global meningococcal vaccines market demonstrates a strong and structured growth outlook, underpinned by the rising incidence of invasive meningococcal diseases, expanding immunization coverage, and continuous advancements in multivalent vaccine development. With the market valued at USD 10.61 billion in 2025, projected to reach USD 4.12 billion in 2026, and expected to grow further to USD 9.24 billion by 2034, the market reflects sustained demand for effective preventive solutions against life-threatening meningococcal infections. North America's leadership, accounting for 13.36% market share in 2025, highlights the role of robust healthcare systems, surveillance programs, and routine vaccination schedules, while Asia Pacific's rapid growth underscores increasing access to affordable vaccines and global health initiatives. Despite challenges such as high vaccine costs, cold-chain dependency, and logistical constraints, strong government support, WHO-led programs, and the emergence of pentavalent vaccines covering major serogroups are reinforcing market fundamentals. Overall, the meningococcal vaccines market is positioned for steady long-term expansion, driven by public health priorities, technological innovation, and global efforts to reduce meningitis-related mortality and long-term complications.

Segmentation By Technology

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Others

By Type

  • MenACWY Vaccines
  • MenB Vaccines
  • MenABCWY Vaccines
  • Others

By Age Group

  • Pediatric
  • Adults

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Geography

  • North America (By Technology, Type, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Technology, Type, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Meningitis, By Key Countries/ Regions
  • 4.4. Technological Advancements in Meningococcal Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Technology
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Inactivated
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. MenACWY Vaccines
    • 5.2.2. MenB Vaccines
    • 5.2.3. MenABCWY Vaccines
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Technology
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Inactivated
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. MenACWY Vaccines
    • 6.2.2. MenB Vaccines
    • 6.2.3. MenABCWY Vaccines
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Technology
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Inactivated
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. MenACWY Vaccines
    • 7.2.2. MenB Vaccines
    • 7.2.3. MenABCWY Vaccines
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Technology
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Inactivated
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. MenACWY Vaccines
    • 8.2.2. MenB Vaccines
    • 8.2.3. MenABCWY Vaccines
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Technology
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Inactivated
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. MenACWY Vaccines
    • 9.2.2. MenB Vaccines
    • 9.2.3. MenABCWY Vaccines
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Meningococcal Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Technology
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Inactivated
    • 10.1.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. MenACWY Vaccines
    • 10.2.2. MenB Vaccines
    • 10.2.3. MenABCWY Vaccines
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Serum Institute of India Pvt. Ltd.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Novartis AG
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Walvax Biotechnology Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Hualan Biological Vaccine Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Bio Farma
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. BioNet-Asia.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 2: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 3: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 4: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 5: Global Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 6: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 7: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 8: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 9: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 10: North America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 12: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 13: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 14: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 15: Europe Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 17: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 18: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 19: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 22: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 23: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 24: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 25: Latin America Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Technology, 2021-2034
  • Table 27: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Type, 2021-2034
  • Table 28: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Age Group, 2021-2034
  • Table 29: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Meningococcal Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Meningococcal Vaccines Market Revenue Breakdown (USD billion, %) By Region, 2025 & 2034
  • Figure 2: Global Meningococcal Vaccines Market Value Share (%), By Technology, 2025 & 2034
  • Figure 3: Global Meningococcal Vaccines Market Value Share (%), By Type, 2025 & 2034
  • Figure 4: Global Meningococcal Vaccines Market Value Share (%), By Age Group, 2025 & 2034
  • Figure 5: Global Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 6: Global Meningococcal Vaccines Market Value Share (%), By Region, 2025 & 2034
  • Figure 7: North America Meningococcal Vaccines Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 8: North America Meningococcal Vaccines Market Value Share (%), By Technology, 2025
  • Figure 9: North America Meningococcal Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 10: North America Meningococcal Vaccines Market Value Share (%), By Type, 2025
  • Figure 11: North America Meningococcal Vaccines Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 12: North America Meningococcal Vaccines Market Value Share (%), By Age Group, 2025
  • Figure 13: North America Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 14: North America Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 15: North America Meningococcal Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Meningococcal Vaccines Market Value Share (%), By Country, 2025
  • Figure 17: Europe Meningococcal Vaccines Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 18: Europe Meningococcal Vaccines Market Value Share (%), By Technology, 2025
  • Figure 19: Europe Meningococcal Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 20: Europe Meningococcal Vaccines Market Value Share (%), By Type, 2025
  • Figure 21: Europe Meningococcal Vaccines Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 22: Europe Meningococcal Vaccines Market Value Share (%), By Age Group, 2025
  • Figure 23: Europe Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 24: Europe Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 25: Europe Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 28: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Technology, 2025
  • Figure 29: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 30: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Type, 2025
  • Figure 31: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 32: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Age Group, 2025
  • Figure 33: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 35: Asia Pacific Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Meningococcal Vaccines Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 38: Latin America Meningococcal Vaccines Market Value Share (%), By Technology, 2025
  • Figure 39: Latin America Meningococcal Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 40: Latin America Meningococcal Vaccines Market Value Share (%), By Type, 2025
  • Figure 41: Latin America Meningococcal Vaccines Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 42: Latin America Meningococcal Vaccines Market Value Share (%), By Age Group, 2025
  • Figure 43: Latin America Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 45: Latin America Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Technology, 2025 & 2034
  • Figure 48: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Technology, 2025
  • Figure 49: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Type, 2025 & 2034
  • Figure 50: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Type, 2025
  • Figure 51: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Age Group, 2025 & 2034
  • Figure 52: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Age Group, 2025
  • Figure 53: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Distribution Channel, 2025
  • Figure 55: Middle East & Africa Meningococcal Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Meningococcal Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Meningococcal Vaccines Market Share (%), By Company, 2025